One of the most trivial examples is the history of malaria vaccine development where the most established vaccine (RTS,S), a recombinant protein containing regions of the Plasmodium circumsporozoite protein (CSP) and targeting the sporozoites stage of the parasite confers less than 40% of protection [146, 147]. This evidence concerns the gene DNAJC5 and malaria.